Clinical Scorecard: Nicox Releases NCX 470 Data
At a Glance
| Category | Detail |
|---|---|
| Condition | Open-angle glaucoma and ocular hypertension |
| Key Mechanisms | Nitric oxide (NO)–donating prostaglandin analog enhancing aqueous humor outflow |
| Target Population | Patients with open-angle glaucoma and ocular hypertension |
| Care Setting | Clinical trials |
Key Highlights
- NCX 470 achieved mean diurnal IOP of ≤18 mmHg in a greater proportion of eyes compared to latanoprost.
- Statistical significance was reached at four out of six time points in the Mont Blanc trial.
- The Mont Blanc trial did not meet the secondary efficacy endpoint of superiority over latanoprost.
- NCX 470 is currently in pivotal phase 3 Denali trial and phase 3b Whistler trial.
- New Drug Application filing with the FDA is anticipated in 2026.
Guideline-Based Recommendations
Diagnosis
- Monitor intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
Management
- Consider NCX 470 as a treatment option based on ongoing trial results.
Monitoring & Follow-up
- Evaluate IOP changes at multiple time points post-treatment initiation.
Risks
- Potential for adverse effects associated with prostaglandin analogs.
Patient & Prescribing Data
Patients with open-angle glaucoma and ocular hypertension.
NCX 470 shows promise in lowering IOP effectively compared to standard treatments.
Clinical Best Practices
- Incorporate findings from ongoing trials into treatment planning.
- Stay updated on the results of the Denali and Whistler trials.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.